| Methods |
RCT
Triple‐blind
1993‐1994 |
| Participants |
Number: 276 patients (315 episodes)
Age: med 56, range 18‐82 |
| Interventions |
cefepime 2grx3
versus
ceftazidime 2grx3 |
| Outcomes |
Overall and infection‐related mortality ‐ at 30 days following end of treatment
Clinical and microbiological failure
Superinfection
Drug modifications
Adverse events |
| Notes |
MC USA |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Computer generated sequence. Patients were stratified and randomized based on whether they had a solid tumor or hematologic malignancy. |
| Allocation concealment? |
Low risk |
Central |
| Blinding?
All outcomes |
Low risk |
Triple blind: patient, carer and an independent reviewer, blinded with respect to treatment assignment assigned clinical responses |
| Incomplete outcome data addressed?
All‐cause mortality |
Low risk |
|
| Incomplete outcome data addressed?
Treatment failure |
High risk |
Number of dropouts (7%) known per study group |
| Free of other bias? |
Low risk |
|
